Skip to main content
TipRanks
Go Ultimate75% OFF

Electrocore (43E0) Q3 2026 Earnings Report

0 Followers

DE:43E0 Q3 2026 EPS Results

Actual EPS
-EUR 0.12
Consensus EPS
-EUR 0.24
Beat/Miss
Beat by +EUR 0.13
One Year Ago EPS
-EUR 0.36

DE:43E0 Q3 2026 Revenue Results

Actual Revenue
EUR 8.68M
Expected Revenue
EUR 9.78M
Beat/Miss
Missed by -EUR 1.11M
YoY Revenue Growth
+11.52%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/04/2026
Time
After Close
Conference Call
Wednesday, November 4, 2026
DE:43E0 Upcoming Earnings

Electrocore's next earnings date is estimated for March 11, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:43E0 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 04, 2026|% Change Since:-35.36%|
Earnings Call Sentiment|Positive

The call was predominantly positive, marked by record revenue, improved gross margin, sharply reduced losses, stronger sales-force productivity, broader VA coverage, increasing Quell adoption and a regulatory submission that could open a new indication. The main negatives were the reduction and timing shift in 2026 guidance, the delayed path to positive adjusted EBITDA, lower Truvaga direct-to-consumer revenue, a refill rate below the company's goal and ongoing FDA and over-the-counter product timing uncertainty.

Company Guidance

ElectroCore revised full year 2026 revenue guidance to $39 million to $42 million from prior guidance of greater than 30% year-over-year growth, said the acceleration expected in the second half of 2026 is now expected in 2027, and provided preliminary 2020 revenue growth guidance of 30% to 40% year-over-year, later described as a 30% to 40% increase in 2027 revenue over 2026 revenue; based on gross margins in the upper 80s on a streamlined cost base, existing cash on hand and financing resources, the company currently believes it can achieve its first fiscal quarter of positive adjusted EBITDA by the end of 2027 without entering into a new dilutive equity capital financing transaction. The company expects refill rate improvements to begin to be recognized in Q4 with additional improvements to be expected in early 2027, with a goal to take the national refill rate above 70% from 42% year-to-date through September; sales targets are about 14 new patients per month per account, about 2 patients per week for gammaCore and about 1.5 to 2 per week for fibromyalgia.

  • Record Quarterly Revenue and Improved ProfitabilityThird-quarter net sales reached a company-record $9.7 million, up approximately 12% year-over-year from $8.7 million. Gross margin expanded to 88.5% from 86% in the prior-year period and 86.5% in the second quarter, while loss from operations narrowed to $1.6 million.
  • Lowest-Ever Adjusted EBITDA LossAdjusted EBITDA loss improved to a company-record low of $700,000 from $2 million in the third quarter of 2025, an improvement of approximately $1.4 million or 67% year-over-year.
  • GAAP Net Loss and Per-Share Loss ImprovedGAAP net loss was $1.3 million compared with $3.4 million in the third quarter of 2025 and $3.1 million in the second quarter of 2026. Net loss per share improved to $0.13 from $0.40 in the prior-year period. The quarter included approximately $400,000 of other income from a settlement of indemnification claims and a $100,000 income-tax benefit.
  • Lower Operating Expense BaseTotal operating expenses declined to $10.1 million from $10.4 million in the third quarter of 2025. Research and development expense decreased to $400,000 from $700,000 year-over-year and $800,000 in the second quarter, while selling, general and administrative expense was $9.7 million, down from $10.1 million in the second quarter.
  • Improved Revenue Quality and Advertising EfficiencyManagement said it is prioritizing durable, repeatable and profitable revenue rather than short-term top-line growth. Although Truvaga direct-to-consumer revenue declined year-over-year, return on advertising spend improved 8% year-over-year as the company avoided increased spending in a market where competitors bidding on Truvaga's branded search term rose 60% and cost per click increased roughly 42%.
  • FDA Submission for CIPN IndicationOn October 27, electroCore filed a 510(k) premarket notification with the FDA seeking clearance for Quell for chemotherapy-induced peripheral neuropathy, following the device's FDA breakthrough designation received in January 2022. Management said the submission is under review and that the earliest response would likely be in the second half of the first quarter, with potential sales beginning in the back half of 2027 if cleared.
  • Potentially Large CIPN OpportunityManagement stated that there is currently no medical device or pharmaceutical product specifically cleared or approved for CIPN. It estimated a United States addressable market of roughly 600,000 to 700,000 people and a VA opportunity of roughly 15,000 to 20,000 people, with potential to pursue both federal and non-federal markets.
  • Sales Organization Expansion and Productivity GainsThe company split its sales leadership into East and West area vice presidents overseeing six regions, added two regional sales directors in October with a third soon to follow, and expanded independent representative coverage. Representatives added since June averaged approximately $210,000 per month in VA revenue in the third quarter versus $160,000 per month in the territories before they arrived, a 30% increase, and were trending toward $300,000 per month in October. Their September revenue was 62% higher than in June 2026.
  • Faster Account and Patient RampNew representatives are reaching revenue and new-account milestones in roughly two months compared with six to seven months previously. By the third month, new patient starts reached 3.4 per account versus 0.3 for previously onboarded representatives.
  • Record Regional Revenue and Broader VA CoverageThe Southeast and Northeast regions each delivered their highest quarterly revenue in company history. The company opened seven VA accounts in the third quarter that had never used its products, representing roughly a 5% increase over the second quarter, while the percentage of staff facilities not carrying gammaCore declined to 28% from 34% between June and September.
  • Reduced Revenue ConcentrationThe top 15 accounts represented 51% of revenue in the third quarter versus 54% in the second quarter. The top 30 accounts represented 71% of VA revenue versus 73% in the second quarter, and no single facility accounted for more than 10% of VA net sales in the third quarter.
  • Quell Fibromyalgia Adoption MomentumQuell fibromyalgia had its best month on record in October, and the company surpassed 1,000 VA patients prescribed Quell in 2026. Management also said October dollar revenue and new patient orders were higher than January and February combined.
  • Growth in VA New Patient OrdersNew patient orders for all products from the VA rose 21% year-over-year in the third quarter.
  • Record Refill Revenue and Patient-Training InitiativeRefill revenue grew 10% from the second quarter to the highest level in company history. The national refill rate was 42% year-to-date through September, and the company is piloting a patient-training initiative intended to improve compliance and increase refill rates, with improvements expected to begin in the fourth quarter and continue into early 2027.
  • Expanded Level Government Services DistributionLevel Government Services accounted for approximately 91% of VA orders in September 2026, up from roughly 57% in June 2026, and became the primary channel for prescription product sales to the VA and Department of Defense. Management expects the shift to reduce related transaction fees by 3% and free internal resources to focus on new and emerging markets.
  • New Commercial and Federal Market DevelopmentPfizer engaged in coverage discussions for its outside California market, and California conducted a Quell evaluation with results described as encouraging. The company also engaged Department of Defense and TRICARE stakeholders, identified pilot areas for federal workers' compensation, initiated contracts for VA Women's Health and first-responder consultants, and began discussions with national opinion leaders.
  • Air Force Research and First-Responder OpportunitiesManagement highlighted clinical-study data from the Air Force Research Lab showing benefits in healthy participants for physical and mental performance. It said the data may be transferable to other high-stress roles, including air traffic controllers, police, SWAT teams, Port Authority personnel, first responders and other military-related opportunities.
  • 2027 Growth and Adjusted EBITDA TargetsThe company provided preliminary 2027 revenue growth guidance of 30% to 40% year-over-year. Based on achieving that growth, gross margins in the upper 80s and a streamlined cost base, management currently believes it can reach its first fiscal quarter of positive adjusted EBITDA by the end of 2027 without entering into a new dilutive equity capital financing transaction.
  • Potential Balance-Sheet SupportThe company is evaluating options to refinance its existing term loan, including extending the timing of principal repayments. Management said this could provide additional support for its cash runway and balance sheet, although no agreement has been entered into and there can be no assurance that one will be completed.

DE:43E0 Earnings History

DE:43E0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 11, 20272026 (Q4)-0.14--0.3――
Nov 04, 20262026 (Q3)-0.24-0.12-0.3667.50% (+0.24)
Aug 06, 20262026 (Q2)-0.38-0.30-0.3925.00% (+0.10)
May 06, 20262026 (Q1)-0.55-0.53-0.42-25.53% (-0.11)
Mar 19, 20262025 (Q4)-0.36-0.30-0.338.11% (+0.03)
Nov 05, 20252025 (Q3)-0.36-0.36-0.28-29.03% (-0.08)
Aug 06, 20252025 (Q2)-0.29-0.39-0.34-15.79% (-0.05)
May 07, 20252025 (Q1)-0.43-0.42-0.4711.32% (+0.05)
Mar 12, 20252024 (Q4)-0.27-0.33-0.5539.34% (+0.21)
Nov 13, 20242024 (Q3)-0.29-0.28-0.6154.41% (+0.33)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed